Back to Oncology
Oncologyv1998Evidence-Based

D'Amico Risk Classification for Prostate Cancer

Assesses 5-year risk of treatment failure in patients with localized prostate cancer based on clinical factors. Stratifies patients into low, intermediate, or high-risk groups to guide treatment decisions and prognosis estimation.

Clinical Input Parameters

ng/mL
Range: 0.1 — 500 ng/mL
years
Range: 40 — 100 years
Clinical Assessment
Awaiting Parameters
risk assessment
—category
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The D'Amico Risk Classification for Prostate Cancer is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Risk group determined by highest risk factor among: PSA level (≤10, 10-20, >20 ng/mL), Gleason score (≤6, 7, ≥8), and clinical stage (T1-T2a, T2b, ≥T2c)

Clinical Pearls & Practice Notes

  • Originally developed for biochemical recurrence prediction after definitive local therapy
  • Widely adopted in clinical practice guidelines (NCCN, EAU, AUA)
  • Based on pre-treatment parameters readily available to clinicians
  • Does not account for newer imaging modalities or genomic markers
  • Intermediate risk group may benefit from further substratification
  • Consider patient comorbidities and life expectancy in treatment decisions
  • Regular surveillance with PSA testing is essential regardless of risk group
  • Risk classification may influence eligibility for clinical trials

Evidence & Literature Citations

  1. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. doi: 10.1001/jama.280.11.969.
  2. D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000;18(6):1164-1172. doi: 10.1200/JCO.2000.18.6.1164.
  3. Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64(6):895-902. doi: 10.1016/j.eururo.2013.03.033.
  4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

Score Interpretation Ranges

Low Risk≤ pts

Low risk of treatment failure

Intermediate Risk≤ pts

Intermediate risk of treatment failure

High Risk≤ pts

High risk of treatment failure

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.